Y Combinator startup transforms 100 million fragmented patient records into multimodal training data and reinforcement learning environments for medical AI agents.

Y Combinator 初创公司将1亿条分散的患者记录转化为多模态训练数据和医疗AI智能体的强化学习环境。

SAN FRANCISCO

旧金山

,

，

Oct. 22, 2026

2026年10月22日

/PRNewswire/ --

/美通社/ --

BioStack

生物堆栈

, a healthcare technology company, announced today that it's launching a data infrastructure network to power the next era of medicine. It spans a global footprint across the U.S., India, Brazil, and Argentina with over 100 million de-identified patient records. By connecting fragmented clinical information, BioStack gives AI and biotech companies the high-quality data needed to train models that understand how disease unfolds, how treatments work, and what drives patient outcomes..

医疗科技公司BioStack今日宣布，推出一项数据基础设施网络，为医学的下一个时代提供动力。该网络覆盖美国、印度、巴西和阿根廷的全球布局，拥有超过1亿条去标识化的患者记录。通过连接分散的临床信息，BioStack为人工智能和生物技术公司提供高质量数据，用于训练能够理解疾病发展过程、治疗作用机制以及影响患者预后因素的模型。

Continue Reading

继续阅读

From left to right: Sanat Mishra (CEO) and Parth Patwa (CTO)

从左至右：Sanat Mishra（首席执行官）和 Parth Patwa（首席技术官）

The company also announced $9.5 million in seed funding led by Peak XV, Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures, and Y Combinator. The round will support BioStack's continued expansion across the United States and international markets, development of its technology platform and growth of its engineering and research teams..

该公司还宣布完成950万美元的种子轮融资，由Peak XV、Afore Capital、DCVC、Emerson Collective、SV Angel、Verdict Capital、Streamlined Ventures和Y Combinator领投。本轮融资将支持BioStack在美国及国际市场的持续扩张，推动其技术平台的开发，并促进其工程和研究团队的成长。

Today, patient histories and other clinical data are often fragmented across hospitals, providers and technology systems, leaving clinicians without a complete picture of a patient's treatment. BioStack creates workflows that bring together clinical information across disparate health systems and geographies.

如今，患者病史和其他临床数据往往分散在不同的医院、医疗机构和技术系统中，导致临床医生无法全面了解患者的治疗情况。BioStack 创建工作流，将跨越不同医疗系统和地理区域的临床信息整合在一起。

Connecting notes, labs, imaging, medications, treatments and outcomes, BioStack provides a more comprehensive view of the patient and informs population-level and hospital-level discovery..

BioStack 通过整合病历笔记、实验室检查、影像学资料、用药记录、治疗方案及预后结果，提供更全面的患者视图，并助力人群层面和医院层面的医学发现。

'Collecting every event linked to each patient enables a view of what happens at each stage of a patient's journey.' said Sanat Mishra, co-founder and CEO of BioStack. 'We're building the infrastructure that connects all of the clinical information and makes it useful, both for clinicians making decisions today and for the researchers and AI developers building the future of medicine.'.

“收集与每位患者相关的每一事件，能够让我们全面了解患者在诊疗旅程各个阶段的情况。”BioStack 联合创始人兼首席执行官 Sanat Mishra 表示。“我们正在构建连接所有临床信息的基础设施，使其发挥实际价值，既服务于当下做出临床决策的医生，也服务于塑造医学未来的研究人员和人工智能开发者。”

In addition to creating custom workflows that protect patient privacy and are based on individual provider protocols, BioStack creates proprietary datasets from de-identified data that it collects from each provider system. These datasets can support medical research, drug development and the training and evaluation of healthcare AI models..

除了创建保护患者隐私并基于各医疗服务提供者个体协议的自定义工作流外，BioStack 还利用从各提供者系统收集的脱敏数据构建专有数据集。这些数据集可支持医学研究、药物开发以及医疗人工智能模型的训练与评估。

It connects biological and clinical data with treatment histories and long-term outcomes. This helps researchers understand what happened to a patient and how different interventions affected their health over time.

它将生物和临床数据与治疗史及长期结局相连接。这有助于研究人员了解患者的病情演变，以及不同干预措施如何随时间影响其健康状况。

BioStack creates a feedback loop between clinical care and medical innovation. As more longitudinal patient information becomes available, researchers and AI developers can gain a richer understanding of disease progression and treatment response. Healthcare providers can benefit from new insights and more personalized approaches to care..

BioStack在临床护理与医疗创新之间构建了一个反馈循环。随着越来越多的纵向患者信息可用，研究人员和人工智能开发人员能够更深入地理解疾病进展和治疗反应。医疗保健提供者则可以从新的洞察和更加个性化的护理方法中受益。

In India, BioStack is helping connect cancer patients with an investigational cancer vaccine program. Patients' clinical data can support biotech companies' development efforts, while eligible patients may gain access to highly personalized investigational treatments.

在印度，BioStack 正在帮助癌症患者与一项研究性癌症疫苗项目建立联系。患者的临床数据可以支持生物科技公司的发展工作，而符合条件的患者则可能获得高度个性化的研究性治疗机会。

BioStack has combined more than several hundred thousand fragmented X-Rays, MRIs, CT scans with other pathology and clinical records. The resulting dataset provides a powerful resource for training AI agents to help clinicians evaluate treatment options and likely patient outcomes.

BioStack 已将数十万份分散的 X 光片、MRI 和 CT 扫描图像与其他病理及临床记录相结合。由此产生的数据集为训练人工智能代理提供了强大的资源，以帮助临床医生评估治疗方案和预测患者可能的预后。

'The next frontier of healthcare AI will depend not only on better models, but on access to high-quality, longitudinal data that reflects how patients are treated over time,' said Pushpak Kedia, Vice President, Peak XV. 'Sanat and the BioStack team are building critical infrastructure that connects fragmented clinical information and transforms it into a valuable resource for clinicians, researchers and AI developers.

Peak XV 副总裁 Pushpak Kedia 表示：“医疗保健人工智能的下一个前沿不仅取决于更优秀的模型，还取决于能否获取高质量、纵向的数据，以反映患者随时间推移的治疗过程。Sanat 与 BioStack 团队正在构建关键基础设施，将分散的临床信息连接起来，并将其转化为临床医生、研究人员和人工智能开发者的宝贵资源。”

We believe BioStack has the potential to become an important data layer for the next generation of medical AI.'.

我们相信 BioStack 有潜力成为下一代医疗 AI 的重要数据层。

BioStack currently works with hospitals across the U.S., Brazil, India and Argentina, giving the company access to a diverse patient population and healthcare environments. Its platform is designed to support applications including medical AI model development and evaluation, clinical research, disease modeling, biomarker discovery, patient stratification and treatment-response analysis..

BioStack 目前与美国、巴西、印度和阿根廷的多家医院合作，使公司能够接触到多样化的患者群体和医疗环境。其平台旨在支持多种应用，包括医学人工智能模型的开发与评估、临床研究、疾病建模、生物标志物发现、患者分层以及治疗反应分析。

About BioStack

关于 BioStack

BioStack is building the data infrastructure for the next generation of healthcare and medical AI. The company connects fragmented clinical information across healthcare systems to create longitudinal patient records spanning notes, labs, imaging, medications, treatment and outcomes. BioStack de-identifies this information to create proprietary datasets that support healthcare research, biotechnology and the development and evaluation of medical AI. .

BioStack 正在为下一代医疗保健和医疗人工智能构建数据基础设施。该公司连接医疗系统中分散的临床信息，创建涵盖病历笔记、实验室检查、影像资料、药物、治疗方案及结果的全周期患者记录。BioStack 对这些信息进行去标识化处理，以创建专有数据集，支持医疗保健研究、生物技术以及医疗人工智能的开发与评估。

BioStack is backed by VC's including Peak XV, Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures, and Y Combinator and operates across the U.S., Brazil, India and Argentina. For more information, visit

BioStack 获得 Peak XV、Afore Capital、DCVC、Emerson Collective、SV Angel、Verdict Capital、Streamlined Ventures 和 Y Combinator 等风险投资机构的支持，业务遍及美国、巴西、印度和阿根廷。欲了解更多信息，请访问

www.getbiostack.com

www.getbiostack.com

.

。

[email protected]

[email protected]

SOURCE BioStack Platforms, Inc.

来源：BioStack Platforms, Inc.

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示